| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Clinical Gene Therapy Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland 20892-1851
A major obstacle to the successful application of suicide gene therapy strategies that rely on in situ transduction of tumor cells is the poor distribution of the vector throughout the tumor mass. To address this problem, we evaluated the use of Ad.TKRC, an E1b Mr 55,000 deleted replicating adenoviral vector engineered to express the herpes simplex virus type 1 thymidine kinase gene (HSV-tk) in combination with ganciclovir (GCV) as a treatment for human colon cancer xenografts in nude mice. We compared the efficacy of this system with that of a standard replication-deficient adenovirus expressing HSV-tk (Ad.TK) in mice bearing LS180 tumors. In this system, Ad.TKRC alone was as effective as a traditional Ad.TK vector in combination with GCV. The addition of GCV significantly enhanced the antitumor effect of Ad.TKRC. Furthermore, we demonstrated that the survival of HT-29 human colon cancer xenografted mice treated with Ad.TKRC and GCV was prolonged compared with Ad.TKRC alone or with administration of a single cycle of topotecan. These data demonstrate that the addition of direct viral oncolysis to the HSV-tk/GCV suicide gene system resulted in a striking improvement in treatment efficacy and that it may offer advantages over the use of chemotherapeutic agents for treatment of localized disease.
This article has been cited by other articles:
![]() |
D. Kuruppu, A.-L. Brownell, A. Zhu, M. Yu, X. Wang, Y. Kulu, B. C. Fuchs, H. Kawasaki, and K. K. Tanabe Positron Emission Tomography of Herpes Simplex Virus 1 Oncolysis Cancer Res., April 1, 2007; 67(7): 3295 - 3300. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Jogler, D. Hoffmann, D. Theegarten, T. Grunwald, K. Uberla, and O. Wildner Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J. Virol., April 1, 2006; 80(7): 3549 - 3558. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-T. Lee, Y.-J. Lee, S.-Y. Kwon, J. Lee, K. I. Kim, K.-H. Park, J. H. Kang, C.-G. Yoo, Y. W. Kim, S. K. Han, et al. In vivo Imaging of Adenovirus Transduction and Enhanced Therapeutic Efficacy of Combination Therapy with Conditionally Replicating Adenovirus and Adenovirus-p27 Cancer Res., January 1, 2006; 66(1): 372 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Seo, M. Abei, M. Wakayama, K. Fukuda, H. Ugai, T. Murata, T. Todoroki, Y. Matsuzaki, N. Tanaka, H. Hamada, et al. Effective Gene Therapy of Biliary Tract Cancers by a Conditionally Replicative Adenovirus Expressing Uracil Phosphoribosyltransferase: Significance of Timing of 5-Fluorouracil Administration Cancer Res., January 15, 2005; 65(2): 546 - 552. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. O. Kirby, A. Rivera, D. Rein, M. Wang, I. Ulasov, M. Breidenbach, M. Kataram, J. L. Contreras, C. Krumdieck, M. Yamamoto, et al. A Novel Ex vivo Model System for Evaluation of Conditionally Replicative Adenoviruses Therapeutic Efficacy and Toxicity Clin. Cancer Res., December 15, 2004; 10(24): 8697 - 8703. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-T. Lee, K.-H. Park, K. Yanagisawa, Y. Adachi, J. E. Ohm, S. Nadaf, M. M. Dikov, D. T. Curiel, and D. P. Carbone Combination Therapy with Conditionally Replicating Adenovirus and Replication Defective Adenovirus Cancer Res., September 15, 2004; 64(18): 6660 - 6665. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Jounaidi and D. J. Waxman Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy Cancer Res., January 1, 2004; 64(1): 292 - 303. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miyagawa, T. Oku, T. Sasajima, R. Dasai, B. Beattie, R. Finn, J. G. Tjuvajev, and R. Blasberg Assessment of Treatment Response by Autoradiography with 14C-Aminocyclopentane Carboxylic Acid, 67Ga-DTPA, and 18F-FDG in a Herpes Simplex Virus Thymidine Kinase/Ganciclovir Brain Tumor Model J. Nucl. Med., November 1, 2003; 44(11): 1845 - 1854. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Moon, Y. Oh, and J. A. Roth Current Status of Gene Therapy for Lung Cancer and Head and Neck Cancer Clin. Cancer Res., November 1, 2003; 9(14): 5055 - 5067. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fukuda, M. Abei, H. Ugai, E. Seo, M. Wakayama, T. Murata, T. Todoroki, N. Tanaka, H. Hamada, and K. K. Yokoyama E1A, E1B Double-restricted Adenovirus for Oncolytic Gene Therapy of Gallbladder Cancer Cancer Res., August 1, 2003; 63(15): 4434 - 4440. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Mullen and K. K. Tanabe Viral Oncolysis for Malignant Liver Tumors Ann. Surg. Oncol., July 1, 2003; 10(6): 596 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H Palmer, M.-J. Chen, and D. J Kerr Gene therapy for colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 201 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Suzuki, R. Alemany, M. Yamamoto, and D. T. Curiel The Presence of the Adenovirus E3 Region Improves the Oncolytic Potency of Conditionally Replicative Adenoviruses Clin. Cancer Res., November 1, 2002; 8(11): 3348 - 3359. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Nettelbeck, A. A. Rivera, C. Balague, R. Alemany, and D. T. Curiel Novel Oncolytic Adenoviruses Targeted to Melanoma: Specific Viral Replication and Cytolysis by Expression of E1A Mutants from the Tyrosinase Enhancer/Promoter Cancer Res., August 15, 2002; 62(16): 4663 - 4670. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Barnes, C. J. Coolidge, A. Hemminki, R. D. Alvarez, and D. T. Curiel Conditionally Replicative Adenoviruses for Ovarian Cancer Therapy Mol. Cancer Ther., April 1, 2002; 1(6): 435 - 439. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Mullen and K. K. Tanabe Viral Oncolysis Oncologist, April 1, 2002; 7(2): 106 - 119. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. S. Haviv, K. Takayama, J. N. Glasgow, J. L. Blackwell, M. Wang, X. Lei, and D. T. Curiel A Model System for the Design of Armed Replicating Adenoviruses Using p53 as a Candidate Transgene Mol. Cancer Ther., March 1, 2002; 1(5): 321 - 328. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. McCart, J. M. Ward, J. Lee, Y. Hu, H. R. Alexander, S. K. Libutti, B. Moss, and D. L. Bartlett Systemic Cancer Therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes Cancer Res., December 1, 2001; 61(24): 8751 - 8757. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hu, J. Lee, J. A. McCart, H. Xu, B. Moss, H. R. Alexander, and D. L. Bartlett Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene Therapy J. Virol., November 1, 2001; 75(21): 10300 - 10308. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Xu and H. L. McLeod Strategies for Enzyme/Prodrug Cancer Therapy Clin. Cancer Res., November 1, 2001; 7(11): 3314 - 3324. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Doronin, M. Kuppuswamy, K. Toth, A. E. Tollefson, P. Krajcsi, V. Krougliak, and W. S. M. Wold Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy J. Virol., April 1, 2001; 75(7): 3314 - 3324. [Abstract] [Full Text] |
||||
![]() |
D. T. Curiel The Development of Conditionally Replicative Adenoviruses for Cancer Therapy Clin. Cancer Res., September 1, 2000; 6(9): 3395 - 3399. [Abstract] [Full Text] |
||||
![]() |
O. Wildner and J. C. Morris The Role of the E1B 55 kDa Gene Product in Oncolytic Adenoviral Vectors Expressing Herpes Simplex Virus-tk: Assessment of Antitumor Efficacy and Toxicity Cancer Res., August 1, 2000; 60(15): 4167 - 4174. [Abstract] [Full Text] |
||||
![]() |
K. Doronin, K. Toth, M. Kuppuswamy, P. Ward, A. E. Tollefson, and W. S. M. Wold Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein J. Virol., July 1, 2000; 74(13): 6147 - 6155. [Abstract] [Full Text] |
||||
![]() |
T. A. Steele Recent Developments in the Virus Therapy of Cancer Experimental Biology and Medicine, February 1, 2000; 223(2): 118 - 127. [Abstract] [Full Text] |
||||
![]() |
J. C. Morris Enzyme/Prodrug-Based Tumor Vaccination: All Politics (and Immunity) Are Local J Natl Cancer Inst, December 1, 1999; 91(23): 1986 - 1989. [Full Text] [PDF] |
||||
![]() |
X. Zheng, M. Johansson, and A. Karlsson Retroviral Transduction of Cancer Cell Lines with the Gene Encoding Drosophila melanogaster Multisubstrate Deoxyribonucleoside Kinase J. Biol. Chem., December 8, 2000; 275(50): 39125 - 39129. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |